Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aptuit Acquires Exquiron Biotech | Contract Pharma

What are you searching for?

Sign in
Breaking News

Aptuit Acquires Exquiron Biotech

Expands early phase drug discovery services

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Aptuit, LLC has acquired Exquiron Biotech AG, a specialist Contract Research Organization dedicated to early phase drug discovery services.
 
Located near Basel, Switzerland, Exquiron offers assay development for hit finding and profiling, high throughput screening, selectivity testing and hit characterization. The company also has an extensive library collection of lead like compounds, as well as scientific knowledge in compound selection and Structure Activity Relationship (SAR) expansion across a range of targets in multiple therapeutic areas.  
 
Dr. Jonathan Goldman, chief executive officer of Aptuit said, “The acquisition of Exquiron broadens our scientific excellence in advanced integrated discovery by incorporating capabilities in early discovery. In particular, we are thrilled to enhance our hit identification, validation, and expansion services. We can now offer uninterrupted and high quality delivery of a research program from target to high quality candidate nomination. We expect our customers to benefit from improved probability of candidate nomination, with reductions in time and cost.”
 
Dr. Stephan Fasler, chief executive officer and founder of Exquiron added, “We are excited to join Aptuit, a highly respected leader in the discovery and development CRO sector. Our customers can now combine our expertise in assay development and high throughput screening with the ability to translate seamlessly to candidate nomination and IND filing. Exquiron and Aptuit share a culture and commitment to scientific excellence, making this a very good fit.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics